Argenica Therapeutics Reports Positive Results From Preclinical Study for Traumatic Brain Injury

MT Newswires Live
02-04

Argenica Therapeutics (ASX:AGN) said that its ARG-007 neuroprotective peptide drug candidate "significantly" reduced damage to brain cells caused by moderate traumatic brain injury in a preclinical rat study, according to a Tuesday Australian bourse filing.

The study assessed ARG-007 regarding the reduction of axonal injury and neuroinflammation seen following moderate traumatic brain injury and resulting behavioral outcomes.

It was found to protect brain cells in the injured brain by reducing axonal injury following injury, as measured by key axonal injury biomarkers neurofilament heavy protein and amyloid precursor protein.

The animals treated with the candidate also showed signs of improvement in a motor function test as well as a significant reduction in weight loss.

The data verifies data received from previous studies.

The firm's shares rose past 1% in recent trading on Tuesday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10